Date: 2015-02-26
Type of information: R&D agreement
Compound: TRPH 011
Company: Triphase Accelerator (Canada - USA - CA) Sunnybrook Research Institute (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: bispecific antibody. TRPH 011 is a novel, first-in-class, fully human bispecific antibody that binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis in animal models of cancer. VEGF and TIE 2 pathways, two important routes for formation of new blood vessels in various tumors, are critical for tumor growth and survival. The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational and validated target for cancer therapy. Triphase entered into a global licensing deal with PharmAbcine for TRPH 011 in 2014. The agreement provides Triphase with global development and commercial rights, except China and Korea.
Disease:
Details: * On February 26, 2015, Triphase Accelerator announced that it has entered into an academic center collaboration with Sunnybrook Research Institute in Toronto to assist in the development of Triphase’s novel, first-in-class, fully human bispecific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis.
Under the terms of the agreement, Triphase will provide funding to the laboratory of Robert S. Kerbel, Ph.D., senior scientist in the Biological Sciences Platform at Sunnybrook Research Institute of the Sunnybrook Health Sciences Centre in Toronto. Dr. Kerbel and his colleagues will evaluate TRPH 011 in preclinical pharmacology models. Triphase will use the findings to advance the TRPH 011 program toward an Investigational New Drug (IND) filing.
In addition to his role at Sunnybrook, Dr. Kerbel is a professor in the Department of Medical Biophysics at the University of Toronto. He holds a Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy. His main research interest is devising new strategies to improve the efficacy of cancer treatments and reduce toxicity. His research has focused on understanding the basis of tumor angiogenesis and designing new therapeutic strategies for advanced metastatic disease based on vascular targeting and inhibition of tumor angiogenesis. He has elucidated mechanisms of VEGF-pathway targeting drugs and development of resistance to them, linked the fields of angiogenesis and oncogenes, and uncovered mechanisms by which antiangiogenic drugs increase chemotherapy efficacy and alter malignant tumor progression.
Financial terms: Under the terms of the agreement, Triphase will provide funding to the laboratory of Robert S. Kerbel, Ph.D., senior scientist in the Biological Sciences Platform at Sunnybrook Research Institute of the Sunnybrook Health Sciences Centre in Toronto.
Latest news:
